<DOC>
	<DOCNO>NCT02445586</DOCNO>
	<brief_summary>Study Pertuzumab ( In Combination Trastuzumab Docetaxel ) Indian Patients Breast Cancer</brief_summary>
	<brief_title>Safety Study Pertuzumab ( In Combination With Trastuzumab Docetaxel ) Indian Patients With Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Pertuzumab</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>1 . Male female patient age &gt; /= 18 year 2 . Signed write informed consent approve relevant Institutional Review Board/Ethics Committee , prior study procedure 3 . For woman childbearing potential men partner childbearing potential , agreement use highlyeffective nonhormonal form contraception two effective form nonhormonal contraception patient and/or partner . 4 . Histologically cytologically confirm documented adenocarcinoma breast metastatic locally recurrent disease amenable curative resection ; patient measurable and/or nonmeasurable disease eligible 5 . Known document HER2positive 6 . Known documented leave ventricular ejection fraction ( LVEF ) least 50 % 7 . Adequate organ function 1 . Previous systemic nonhormonal anticancer therapy metastatic locally recurrent disease 2 . Pregnant lactate woman 3 . Current clinical radiographic evidence central nervous system ( CNS ) metastases 4 . Disease progression receive within 12 month completion trastuzumab and/or lapatinib treatment adjuvant neoadjuvant setting</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>